Therapeutic potential for orally administered type 1 interferons

Pharmaceutical Science and Technology Today

Volumn 3, Issue 6, 2000, Pages 193-197

  Beilharz, Manfred W ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Administration; Cytokine; Immunology; Interferon; Mucosal; Oral; Pharmaceutical science

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON;

CANCER; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOXICITY; HUMAN; REVIEW; SIDE EFFECT; STANDARDIZATION; VIRUS INFECTION;

EID: 0034214147     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(00)00264-9     Document Type: Review

References (66)

1. Rollwagen F.M., Baqar S. Oral cytokine administration. Immunol. Today. 17:1996;548-550.
2. Bocci V. Absorption of cytokines via the oropharyngeal associated lymphoid tissues: does an unorthodox route improve the therapeutic index of interferon? Clin. Pharmacokinet. 21:1991;411-417.
3. Shiozawa S.et al. Single-blinded controlled trial of low-dose oral interferon-α for the treatment of xerostomia in patients with Sjögren's syndrome. J. Interferon Cytokine Res. 18:1998;255-262.
4. Ship J.A.et al. Treatment of primary Sjögren's syndrome with low-dose natural human IFN-α administered by the oral mucosal route: a Phase II clinical trial. J. Interferon Cytokine Res. 19:1999;943-951.
5. Schafer T.W.et al. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science. 176:1972;1326-1327.
6. Cummins J.M., Georgiades J.A. How it began. Arch. Immunol. Ther. Exp. 41:1993;169-172.
7. Gresser I.et al. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature. 251:1974;543-545.
8. Havell E.A.et al. Correlation of physiochemical and antigenic properties of human leukocyte interferon sub species. Arch. Virol. 55:1997;121-129.
9. Babiuk L.A., Rouse B.T. Bovine type II interferon: activity in heterologous cells. Intervirology. 8:1977;250-256.
10. Lin L.S.et al. Characterization of the heterologous molecules of human interferons: differences in the cross-species antiviral activities of various molecular populations in human leukocyte interferons. J. Gen. Virol. 39:1978;125-130.
11. Tovey M.G.et al. Antiviral activity of bovine interferons on primate cells. J. Gen. Virol. 36:1977;341-344.
12. Tompkins M.D., Cummins J.M. Response of feline leukemia virus-induced nonregenerative anemia to oral administration of an interferon-containing preparation. Feline Pract. 12:1982;6-15.
13. Cummins J.M., Hutcheson D.P. Effect of interferon on feedlot calves. Proc. Am. Assoc. Bovine Pract. 15:1983;109-115.
14. Cummins J.M., Hutcheson D.P. Low dosage of interferon to enhance vaccine efficiency in feedlot calves. Proc. Am. Assoc. Bovine Pract. 18:1986;135-138.
15. Steed V.P. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract. 17:1987;24-30.
16. Diez R.A.et al. From old results to new perspectives: a look at interferon's fate in the body. J. Interferon Res. 7:1987;553-557.
17. 125I]-interferon (IFN) alpha-A. Cantell K., Schellekens H. The Biology of the Interleukin System. 1986;549-556 Martinus Nijhoff, Dorcrecht, The Netherlands.
18. Cantell K., Pyhala L. Circulating interferon in rabbits after administration of human interferon by different routes. J. Gen. Virol. 20:1973;97-104.
19. Gibson D.M.et al. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J. Interferon Res. 5:1985;403-408.
20. Wills R.J.et al. Pharmacokinetics of recombinant alpha A interferon following IV infusion and bolus, IM and PO administration to African green monkeys. J. Interferon Res. 4:1984;399-409.
21. Gresser I., Dull H.B. A virus inhibitor in pharyngeal washings from patients with influenza. Proc. Soc. Exp. Biol. Med. 115:1964;192-195.
22. Waddell D.J.et al. Interferon production in human mumps infections. Proc. Soc. Exp. Biol. Med. 127:1968;320-324.
23. Cummins J.M.et al. Oral use of interferon. J. Interferon Cytokine Res. 19:1999;853-857.
24. Haff R.F.et al. Pathogenesis of influenza in ferrets. J. Immunol. 96:1966;659-667.
25. Greenberg S.B.et al. Activity of exogenous interferon in the human nasal mucosa. Texas Reports Biol. and Med. 35:1977;491-495.
26. Fujioka N.et al. Potential application of human interferon-α in microbial infections of the oral cavity. J. Interferon Cytokine Res. 15:1995;1047-1051.
27. Smith J.K.et al. Effect of interferon α on HLA-DR expression by human buccal epithelial cells. Arch. Immunol. Ther. Exp. 44:1996;83-88.
28. Ohashi K.et al. Effects of interferon-α on a reduced release of interleukin-8 from latently HIV-1-infected monocytic cell line U937 cells. J. Interferon. Res. 14:1994;129-132.
29. Dao T.et al. Natural human interferon-α enhances the expression of intercellular adhesion molecule-1, integrin α2 and β1 by a mucosal epithelial cell line. Folia Biologica (Praha). 41:1995;213-225.
30. Cummins J.M.et al. Oral use of human alpha interferon in cats. J. Biol. Resp. Mod. 7:1988;513-523.
31. Gilger B. The use of low dose oral interferon alpha to increase tear production in dogs with Keratoconjunctivitis sicca. J. Interferon Cytokine Res. 19:1998;901-905.
32. Young A.S.et al. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitology. 101:1990;201-209.
33. Cummins J.M.et al. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch. Immunol. Ther. Exp. 41:1993;193-197.
34. Georgiades J.A. Effect of low dose natural human interferon alpha given into the oral cavity on the recovery time and death loss in feedlot hospital pen cattle: a field study. Arch. Immunol. Ther. Exp. 41:1993;205-207.
35. Moore B.R.et al. Changes in airway inflammatory cell populations in standardbred racehorses after interferon-alpha administration. Vet. Immunol. Immunopathol. 49:1996;347-358.
36. Lecce J.G.et al. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Mol. Biother. 2:1990;211-216.
37. Cummins J.M.et al. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet. Immunol. Immunopathol. 45:1995;355-360.
38. Yoshino S. The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Exp. Molec. Path. 62:1995;123-130.
39. Brod S.A.et al. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J. Interferon Cytokine Res. 15:1995;115-122.
40. Yoshino S. Effects of oral administration of type I interferon on adjuvant arthritis in rats. Comp. Immunol. Microbiol. Infect. Dis. 19:1996;133-138.
41. Nelson P.A.et al. Effect of oral beta interferon on subsequent immune responsiveness. Ann. New York Acad. Sci. 778:1996;145-155.
42. Satoh Y.et al. Induction of tissue 2′5′ AS and suppression of delayed type of asthma reaction by oral administration of IFN-β in guinea pig asthma model. J. Interferon Cytokine Res. 17:1997;S96.
43. Koech D.K.et al. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Mol. Biother. 2:1990;91-95.
44. Jordan W.C. Three open-label studies of oral interferon alpha in the treatment of HIV disease. J. Nat. Med. Assoc. 86:1994;257-262.
45. Brod S.A.et al. Ingested IFN-α has biological effects in humans with relapsing-remitting multiple sclerosis. Multiple Sclerosis. 3:1997;1-7.
46. Balcerska A.et al. Evaluation of the efficacy of human interferon alpha lozenges on the clinical course of childhood neoplasia and in chronic hepatitis B virus infection in patients who were successfully treated for pediatric malignancies. Arch. Immunol. Ther. Exp. 41:1993;221-228.
47. Ratajczak B. Observation of the effect of low oral doses of human leukocytic interferon alpha in children with chronic HBV infection and impaired immune response. Arch. Immunol. Ther. Exp. 41:1993;237-240.
48. Ericsson A.D., Cummins J.M. Clinical studies of neuromuscular disease. Raum Zeit. 2:1991;26-32.
49. Ericsson A.D., Engle A.C. III Clinical studies phase II: polymyositis. Raum Zeit. 2:1991;10-14.
50. Hutchinson V.A.et al. Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha. Mol. Biother. 2:1990;160-164.
51. Hutchinson V.A.et al. Chronic major aphthous stomatitis: oral treatment with low-dose α-interferon. Mol. Biother. 2:1990;217-220.
52. Lecciones J.A.et al. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-α-n1 (Ins) in pediatric patients with measles. J. Interferon Cytokine Res. 18:1998;647-652.
53. Hulton M.R.et al. Randomized, placebo-controlled, double-blind study of low-dose oral interferon-α in HIV-1 antibody positive patients. J. Acquired Immune Defic. Syndr. 5:1992;1084-1090.
54. Kaiser G.et al. Low-dose oral natural human interferon-α in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 6:1992;563-569.
55. Sperber S.J.et al. Low-dose oral recombinant interferon-αA in patients with HIV-1 infection: a blinded pilot study. AIDS. 7:1993;693-697.
56. Dhingra K.et al. A phase-I clinical study of low-dose oral interferon-α J. Immunother. 14:1993;51-55.
57. Witt P.L.et al. Absence of biological effects of orally administered interferon-βser. J. Interferon Res. 12:1992;411-413.
58. Tovey, M.G. (1997) Stimulation of host defense mechanisms against viral challenges. International Pub. No. WO97/41883
59. Tovey, M.G. (1997) Method of treatment. International Pub. No. WO97/41884
60. Tovey, M.G. (1997) Stimulation of host defense mechanisms against tumors. International Pub. No. WO97/41886
61. Shiozawa S.et al. A preliminary study on interferon-alpha treatment for xerostomia of Sjögrens syndrome. Br. J. Rheumatol. 32:1993;52-54.
62. Ferraccioli G.F.et al. Interferon-α2 increases lacrimal and salivary function in Sjögrens syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin. Exp. Rheumatol. 14:1996;367-371.
63. Beilharz, M.W. and Fleischmann, W.R. (eds) (1999) Special topics issue: Oral use of interferons and cytokines. J. Interferon Cytokine Res. 19, 813-979
64. Siegal F.P.et al. The nature of the principal type 1 IFN-producing cells in human blood. Science. 284:1999;1835-1837.
65. Rollwagen F.M.et al. Systemic bacteraemia following haemorrhagic shock in mice: alleviation with oral interleukin 6. Cytokine. 8:1996;121-129.
66. Georgiades J.A., Fleischmann W.R. Oral application of cytokines. Biotherapy. 8:1996;205-212.